Cargando…

Therapies in Stiff-Person Syndrome: Advances and Future Prospects Based on Disease Pathophysiology

Among the glutamic acid decarboxylase (GAD)-antibody–spectrum disorders, the most common phenotypic subset is the stiff-person syndrome (SPS), caused by impaired GABAergic inhibitory neurotransmission and autoimmunity characterized by very high titers of GAD antibodies and increased GAD-IgG intrathe...

Descripción completa

Detalles Bibliográficos
Autor principal:	Dalakas, Marinos C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119813/ https://www.ncbi.nlm.nih.gov/pubmed/37059468 http://dx.doi.org/10.1212/NXI.0000000000200109

Ejemplares similares

Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies
por: Dalakas, Marinos C.
Publicado: (2022)

Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody–Positive Stiff-Person Syndrome
por: Yi, Jessica, et al.
Publicado: (2022)

Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder
por: Rakocevic, Goran, et al.
Publicado: (2019)

Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies
por: Dalakas, Marinos C.
Publicado: (2018)

Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies
por: Dalakas, Marinos C.
Publicado: (2022)

IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti–B Cell Therapies
por: Dalakas, Marinos C.
Publicado: (2021)

Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease: More to come with myositis in the offing
por: Dalakas, Marinos C.
Publicado: (2020)

Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases
por: Stathopoulos, Panos, et al.
Publicado: (2022)

Therapeutic Antibodies in Neurological Diseases: Witnessing the Continuation of the Impressive Success in Neuro-Immunotherapies
por: Dalakas, Marinos C., et al.
Publicado: (2022)

Objectivity, practicality, and significance of practice guidelines for the practicing neurologists: What we learnt from consensus criteria in CIDP, Myasthenia Gravis and Inflammatory Myopathies
por: Dalakas, Marinos C.
Publicado: (2023)

Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system
por: Dalakas, Marinos C.
Publicado: (2018)

Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications
por: Dalakas, Marinos C.
Publicado: (2020)

Stiff person spectrum disorder diagnosis, misdiagnosis, and suggested diagnostic criteria
por: Chia, Nicholas H., et al.
Publicado: (2023)

Gene therapy for Duchenne muscular dystrophy: balancing good science, marginal efficacy, high emotions and excessive cost
por: Dalakas, Marinos C.
Publicado: (2017)

Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy
por: Dalakas, Marinos C.
Publicado: (2021)

Autoimmune Neurogenic Dysphagia
por: Stathopoulos, Panos, et al.
Publicado: (2021)

Stiff Person Spectrum Disorders—An Update and Outlook on Clinical, Pathophysiological and Treatment Perspectives
por: Vlad, Benjamin, et al.
Publicado: (2023)

The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors
por: Dalakas, Marinos C., et al.
Publicado: (2021)

Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?
por: Kohle, Felix, et al.
Publicado: (2023)

Complement in neurological disorders and emerging complement-targeted therapeutics
por: Dalakas, Marinos C., et al.
Publicado: (2020)

Advances in Molecular Pathophysiology and Targeted Therapy for Cushing’s Disease
por: Takayasu, Shinobu, et al.
Publicado: (2023)

Tremor in Parkinson’s Disease: From Pathophysiology to Advanced Therapies
por: Abusrair, Ali H., et al.
Publicado: (2022)

Aortic stiffness: pathophysiology, clinical implications, and approach to treatment
por: Sethi, Salil, et al.
Publicado: (2014)

Pathophysiology of Takotsubo Syndrome as A Bridge to Personalized Treatment
por: Budnik, Monika, et al.
Publicado: (2021)

The Stiff People: Two Rare Cases of Stiff-person Syndrome
por: Siddiqui, Muhammad Z, et al.
Publicado: (2017)

Association of stiff-person syndrome with autoimmune endocrine diseases
por: Lee, Yi-Yin, et al.
Publicado: (2019)

Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC
por: Dong, Yawen, et al.
Publicado: (2021)

Stiff Person Syndrome Associated with Compartment Syndrome
por: Yong, Kok Pin, et al.
Publicado: (2019)

Recent Advances and Review on Treatment of Stiff Person Syndrome in Adults and Pediatric Patients
por: Bhatti, Adnan Bashir, et al.
Publicado: (2015)

Stiff-Person Syndrome: Case Series
por: Jung, Yu Jin, et al.
Publicado: (2014)

Stiff person syndrome in South Asia
por: Chang, Thashi, et al.
Publicado: (2016)

Stiff-person Syndrome with Waldenström Macroglobulinemia
por: Horiuchi, Kazuhiro, et al.
Publicado: (2018)

Stiff Person Syndrome and Gluten Sensitivity
por: Hadjivassiliou, Marios, et al.
Publicado: (2021)

Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications
por: Dalakas, Marinos C., et al.
Publicado: (2021)

GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions
por: Tsiortou, Popianna, et al.
Publicado: (2021)

Clinico-pathogenetic findings and management of chondrodystrophic myotonia (Schwartz-Jampel syndrome): a case report
por: Ho, Nicola C, et al.
Publicado: (2003)

Efficacy and safety of therapeutic plasma exchange in stiff person syndrome
por: Czempik, Piotr F., et al.
Publicado: (2021)

Cardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne Muscular Dystrophy
por: Meyers, Tatyana A., et al.
Publicado: (2019)

Clinical Spectrum of Stiff Person Syndrome: A Review of Recent Reports
por: Sarva, Harini, et al.
Publicado: (2016)

Recent Advances in the Pathophysiology of Musculocontractural Ehlers-Danlos Syndrome
por: Kosho, Tomoki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ogom40q5p51n6j15s8je3ecd72